
Sign up to save your podcasts
Or


The non-vitamin-K oral anticoagulants (known familiarly as NOACs or DOACs) share metabolic pathways with other drugs, which can potentiate NOACs’ anticoagulant actions dangerously. Dr. Shang-Hung Chang and his group studied Taiwan’s national health insurance database, which records data on virtually all that nation’s citizens, to measure the actual risks of some of these drug – drug interactions. Their findings were published earlier this month in JAMA.
Links:
JAMA article (abstract)
Physician’s First Watch coverage
By NEJM Group4.5
5656 ratings
The non-vitamin-K oral anticoagulants (known familiarly as NOACs or DOACs) share metabolic pathways with other drugs, which can potentiate NOACs’ anticoagulant actions dangerously. Dr. Shang-Hung Chang and his group studied Taiwan’s national health insurance database, which records data on virtually all that nation’s citizens, to measure the actual risks of some of these drug – drug interactions. Their findings were published earlier this month in JAMA.
Links:
JAMA article (abstract)
Physician’s First Watch coverage

7,594 Listeners

319 Listeners

2,058 Listeners

126 Listeners

496 Listeners

293 Listeners

885 Listeners

263 Listeners

3,343 Listeners

112,027 Listeners

90 Listeners

5 Listeners

92 Listeners

513 Listeners

2,550 Listeners

369 Listeners

15,836 Listeners

61 Listeners

31 Listeners

66 Listeners